Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study

NCT04262089 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT04262089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
Lead sponsor
University Medical Center Groningen
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2020
Completion date
November 1, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uterine cancer